Human breast milk: A promising treatment for necrotizing enterocolitis

Early Hum Dev. 2023 Sep:184:105833. doi: 10.1016/j.earlhumdev.2023.105833. Epub 2023 Jul 26.

Abstract

Necrotizing enterocolitis (NEC) is a severe gastrointestinal disorder occurring in newborns, with a mortality rate ranging from 20 % to 30 %. The existing therapeutic approaches for NEC are limited in their effectiveness. Various factors contribute to the development of NEC, including disruption of barrier function, dysregulation of the intestinal immune system, and abnormal colonization of the intestinal microbiota. Researchers have shown considerable interest in exploring the therapeutic potential of the constituents present in human breast milk (HBM) for treating NEC. HBM contains numerous bioactive components, such as exosomes, growth factors, and oligosaccharides. However, the precise mechanisms by which HBM exerts its protective effects against NEC remain incompletely understood. In this study, our objective was to comprehensively review the bioactive substances present in HBM, aiming to facilitate the development of novel therapeutic strategies for NEC.

Keywords: Exosomes; Growth factors; Human breast milk; Necrotizing enterocolitis; Oligosaccharides.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Enterocolitis, Necrotizing*
  • Female
  • Gastrointestinal Microbiome*
  • Humans
  • Infant, Newborn
  • Infant, Newborn, Diseases* / metabolism
  • Milk, Human